Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 117 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3dFB{UUN3ME2wMlA3OSEQvF2= NVLXV2lrW0GQR1XS
ALL-PO NG\JfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;OTWM2OD1yLkC2N|U2KM7:TR?= NGj6UFBUSU6JRWK=
697 M3\2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEm5O|Yh|ryP MXzTRW5ITVJ?
NCI-H748 NGjYWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyyUlZKSzVyPUCuNVA{OzRizszN NXj3N4Z{W0GQR1XS
NKM-1 M3TCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLwWm9nUUN3ME2wMlExQTF{IN88US=> M3PienNCVkeHUh?=
ES1 NW\UdW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrtPZd3UUN3ME2wMlEyOjV3IN88US=> MWnTRW5ITVJ?
NCI-H1963 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMUG1O|kh|ryP M1v3cnNCVkeHUh?=
NCI-H1417 NGW1[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33VZ2lEPTB;MD6xNlk4PCEQvF2= NHXaOoNUSU6JRWK=
NEC8 NUiwVolRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7hSmVCUUN3ME2wMlE{PTJ5IN88US=> MXLTRW5ITVJ?
CRO-AP2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Wb2h[UUN3ME2wMlE3QDh7IN88US=> MWjTRW5ITVJ?
A3-KAW MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjFWHhKSzVyPUCuNVc3OjdizszN M2j2NHNCVkeHUh?=
SF539 M1T3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT5e2ZSUUN3ME2wMlE6PTl|IN88US=> NWTBUHhvW0GQR1XS
NOS-1 MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMUm2NVkh|ryP M4POTHNCVkeHUh?=
NTERA-S-cl-D1 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f3ZWlEPTB;MD6yNFEyOyEQvF2= MmD4V2FPT0WU
COR-L88 M4X1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv5OYVKSzVyPUCuNlI6PTlizszN M3\KV3NCVkeHUh?=
EM-2 NYr1THo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHlXGxKSzVyPUCuNlQxPzlizszN M3H4S3NCVkeHUh?=
KARPAS-45 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmwemg4UUN3ME2wMlI4QDN|IN88US=> MUjTRW5ITVJ?
DSH1 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHlTopKSzVyPUCuNlg4ODhizszN MoHJV2FPT0WU
HT-144 NGLjU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojmTWM2OD1yLkOwNlU3KM7:TR?= MVLTRW5ITVJ?
ATN-1 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwM{C1O|Yh|ryP M1W5PHNCVkeHUh?=
HEL MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTETWM2OD1yLkOxN|Q5KM7:TR?= NWrDcGN2W0GQR1XS
NB12 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fyRmlEPTB;MD6zNVc2PiEQvF2= NUPIZ5dWW0GQR1XS
LU-139 M3j0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{O1NUDPxE1? NX;iXGM5W0GQR1XS
J-RT3-T3-5 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwM{O3NVYh|ryP M3jzRnNCVkeHUh?=
MOLT-13 NUnPRlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwM{O4NUDPxE1? MnPOV2FPT0WU
SR NE\4clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vNe2lEPTB;MD6zOFI3OSEQvF2= MWHTRW5ITVJ?
CMK NUTvNnF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLqUGNbUUN3ME2wMlM2PzJ5IN88US=> NE\J[pVUSU6JRWK=
ES8 Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe4TFZKSzVyPUCuN|YxOjJizszN MXPTRW5ITVJ?
LB647-SCLC NVvVN4J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nNNGlEPTB;MD6zOlc{KM7:TR?= MWfTRW5ITVJ?
TE-8 NUO3WJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwM{[5N|Uh|ryP Mn[zV2FPT0WU
BV-173 NGTYUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\1T5FxUUN3ME2wMlM4OTJzIN88US=> MX\TRW5ITVJ?
DEL M3PDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzZfY9xUUN3ME2wMlM4PDh5IN88US=> MW\TRW5ITVJ?
ARH-77 NYfITnY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\FSFFKSzVyPUCuN|gyQTNizszN NE\UNGpUSU6JRWK=
NCCIT MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljWTWM2OD1yLkO4OlQ6KM7:TR?= MWLTRW5ITVJ?
RPMI-8402 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKxfXJKSzVyPUCuN|g4ODFizszN NVPZRmRpW0GQR1XS
MONO-MAC-6 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwM{i3O|Yh|ryP M1e5NHNCVkeHUh?=
SK-MM-2 MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwM{m4Olgh|ryP MnHrV2FPT0WU
CHP-126 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLHTWM2OD1yLkSwNlMyKM7:TR?= MXrTRW5ITVJ?
A101D NIHvV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwNECzJO69VQ>? NWDNPIU6W0GQR1XS
SCH NYHJWJo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDzTWM2OD1yLkSwN|QzKM7:TR?= MWrTRW5ITVJ?
NMC-G1 NHy1boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX1UHdKSzVyPUCuOFA{PjdizszN MWfTRW5ITVJ?
NCI-H209 NFy5eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfrWphlUUN3ME2wMlQxPjF|IN88US=> MorqV2FPT0WU
MOLT-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm5TWM2OD1yLkSxNFE4KM7:TR?= NWPkTmh5W0GQR1XS
RPMI-6666 NGTK[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwNEGxNkDPxE1? M1r5W3NCVkeHUh?=
OPM-2 NYPGUmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vQWGlEPTB;MD60NVUyOyEQvF2= Mke2V2FPT0WU
MRK-nu-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fReWlEPTB;MD60N|E2OyEQvF2= NUXGbnZTW0GQR1XS
BC-1 NFPvNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjJTZJKSzVyPUCuOFM1ODNizszN MWrTRW5ITVJ?
MHH-NB-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNEO0OVMh|ryP NFq5Z|NUSU6JRWK=
Ramos-2G6-4C10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO5TWM2OD1yLkSzPFk4KM7:TR?= NVu0VWd3W0GQR1XS
LS-513 NXjScFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\3NY9KSzVyPUCuOFQ2ODFizszN MlviV2FPT0WU
K5 NX6wVIM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkV2ppUUN3ME2wMlQ4ODJ3IN88US=> M1XBRnNCVkeHUh?=
HOP-62 M2DkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNEizOVgh|ryP Mkf5V2FPT0WU
NCI-H187 NFvHTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNEmyNlch|ryP NXG5WHk4W0GQR1XS
BE-13 NFXBUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDCTWM2OD1yLkS5OlYyKM7:TR?= NYS5UoRVW0GQR1XS
HC-1 NHTkNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7Cb5VIUUN3ME2wMlUxPDd|IN88US=> NEPFWodUSU6JRWK=
ACN NW\GN3c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXsS41KSzVyPUCuOVExOjhizszN MVrTRW5ITVJ?
HCC1599 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNUG1O{DPxE1? MmLKV2FPT0WU
MV-4-11 M1HST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwNUOwOFEh|ryP MWDTRW5ITVJ?
LC-2-ad NYPCU|lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PWfGlEPTB;MD61N|Y3OyEQvF2= NWTFUVZ[W0GQR1XS
HL-60 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNUSyOlEh|ryP NIfTV4ZUSU6JRWK=
NB17 M1L5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO2Rmc6UUN3ME2wMlU1OzhizszN MnH4V2FPT0WU
TE-1 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULtT2NCUUN3ME2wMlU2OzB4IN88US=> MXPTRW5ITVJ?
NCI-H524 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHLcIZOUUN3ME2wMlU2PDBzIN88US=> MoPCV2FPT0WU
MZ7-mel NYfJXoZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDlTnlKSzVyPUCuOVYyODVizszN NWr1Wm94W0GQR1XS
L-363 NUHpZXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPIWFVKSzVyPUCuOVY3PTdizszN M1rCeHNCVkeHUh?=
BL-41 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwNU[4PFkh|ryP NFvhRYhUSU6JRWK=
LU-134-A NWfNWoVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\5XZVKSzVyPUCuOVcxPzNizszN MVXTRW5ITVJ?
SIG-M5 NWDZcXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;UTWM2OD1yLkW3PFQ5KM7:TR?= NGnkZXpUSU6JRWK=
ONS-76 NEDKZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme3TWM2OD1yLkW4NlQzKM7:TR?= NUfWZolFW0GQR1XS
KARPAS-299 NWjLepM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTOXpBsUUN3ME2wMlU5PTB2IN88US=> MVfTRW5ITVJ?
DU-4475 NGjqNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\aWXpUUUN3ME2wMlU5PzB|IN88US=> NITMbXNUSU6JRWK=
NB69 NIDjSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HETGlEPTB;MD61PVgzPSEQvF2= MWnTRW5ITVJ?
MHH-PREB-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNkC3NVkh|ryP Mne1V2FPT0WU
LU-165 NFfyWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP1TWM2OD1yLk[xPFEzKM7:TR?= MUnTRW5ITVJ?
LOUCY MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLrTWM2OD1yLk[zN|Y1KM7:TR?= MmHmV2FPT0WU
NCI-H526 NHHa[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHafHVKSzVyPUCuOlM2PDFizszN NVH0N3NuW0GQR1XS
KE-37 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL0dXA5UUN3ME2wMlY1Ojd4IN88US=> NIrHVGdUSU6JRWK=
NALM-6 M1XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QNGlEPTB;MD62OFg3KM7:TR?= MWPTRW5ITVJ?
CW-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGruepJKSzVyPUCuOlU4QTRizszN NIP2WW5USU6JRWK=
SU-DHL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fFUmlEPTB;MD62OVk1PyEQvF2= M3rESXNCVkeHUh?=
NB13 M4W5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrRRmxRUUN3ME2wMlY3QDF5IN88US=> NITtcpJUSU6JRWK=
QIMR-WIL NFnVTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwNkizOFMh|ryP NFjKOWNUSU6JRWK=
ECC12 NWrhV45ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvJfIdKSzVyPUCuO|AxQDZizszN NF25XZNUSU6JRWK=
KALS-1 NVn0T4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzjTWM2OD1yLkewOFkzKM7:TR?= NGrnO|BUSU6JRWK=
COR-L279 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7KPFl[UUN3ME2wMlcxQTl4IN88US=> MkSzV2FPT0WU
NB14 NYW2U|hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwN{K2NVch|ryP M2PNd3NCVkeHUh?=
CCRF-CEM MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwN{S2OlEh|ryP NVu5OFNqW0GQR1XS
SW954 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwN{W5PVkh|ryP MYLTRW5ITVJ?
IST-SL1 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[0SplKSzVyPUCuO|c{PDhizszN NIHrSnhUSU6JRWK=
LAMA-84 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv4dWdKSzVyPUCuO|c2PjdizszN M3;2d3NCVkeHUh?=
Daudi NV3wb49FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TcWlEPTB;MD63O|Y5OSEQvF2= NF;sVnpUSU6JRWK=
BC-3 NHnETodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPHT5pKSzVyPUCuO|g{ODhizszN MUTTRW5ITVJ?
HCC2998 M3XBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwN{izOkDPxE1? MWXTRW5ITVJ?
NCI-H69 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfzb5hUUUN3ME2wMlgxOTR5IN88US=> M1i0b3NCVkeHUh?=
CPC-N M{O5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;FWGxKSzVyPUCuPFA2OjRizszN NFr0PVJUSU6JRWK=
NOMO-1 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwOEGwPFQh|ryP M{f0cXNCVkeHUh?=
CESS M3XDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwOEGxPVch|ryP MYTTRW5ITVJ?
LC4-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\wd2FKSzVyPUCuPFQxODdizszN M1fwenNCVkeHUh?=
BL-70 M1LwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwOEW3NFIh|ryP NGjHXIxUSU6JRWK=
ES4 NYC4R5R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPYTJNKSzVyPUCuPFU5PjhizszN NYjZbnF[W0GQR1XS
HCE-T NEHIOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj2W5J4UUN3ME2wMlg4OTdzIN88US=> NV;jOGx5W0GQR1XS
JAR NV3uW45vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4foW2lEPTB;MD64O|gzPyEQvF2= MoOzV2FPT0WU
ST486 NUL1ToxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwOEe5NVch|ryP M3PxfnNCVkeHUh?=
KS-1 NFHCUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvHTWM2OD1yLki4NFk3KM7:TR?= M1\ROXNCVkeHUh?=
GDM-1 NHv4NVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G5NmlEPTB;MD64PFY5PyEQvF2= NILlRpNUSU6JRWK=
EHEB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnSTWM2OD1yLkmyOVg2KM7:TR?= Mki1V2FPT0WU
LB2518-MEL NWjmT2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;zS25KSzVyPUCuPVMzQDRizszN NIrhUYtUSU6JRWK=
GOTO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof4TWM2OD1yLkm1NFc3KM7:TR?= M3PqNnNCVkeHUh?=
LXF-289 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwOUW5NFEh|ryP NYnm[GJqW0GQR1XS
ES6 NIH2O5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO3TWM2OD1yLkm2OFM4KM7:TR?= M3v1U3NCVkeHUh?=
OS-RC-2 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO4TWM2OD1yLkm2PFMh|ryP MlTxV2FPT0WU
DMS-153 NYmzTYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;0fZlGUUN3ME2wMlk4PDZ7IN88US=> MkC0V2FPT0WU
SK-PN-DW NHfMVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwOUe4N|Eh|ryP MXfTRW5ITVJ?
HH NUjPW4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLSXIhKSzVyPUCuPVg6PTlizszN MX7TRW5ITVJ?
SH-4 NIW1bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHJdllKUUN3ME2xMlAzPDFizszN NV\teHI2W0GQR1XS
MOLT-4 NV7M[lJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3C[3hKSzVyPUGuNFM1PTRizszN NI\xV4hUSU6JRWK=
TGW NF;lO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPHTWM2OD1zLkC3Olc2KM7:TR?= MXvTRW5ITVJ?
L-540 M{nZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnMPJh1UUN3ME2xMlExPjB2IN88US=> MXHTRW5ITVJ?
PF-382 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme1TWM2OD1zLkGxOVE{KM7:TR?= NXS1OlV4W0GQR1XS
LC-1F NYOycpJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTITYtCUUN3ME2xMlEzODB5IN88US=> NF7LW2xUSU6JRWK=
OVCAR-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2foVmlEPTB;MT6xN|E3PSEQvF2= NFTYUHZUSU6JRWK=
A4-Fuk NVrBS|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PIW2lEPTB;MT6xOVM3PCEQvF2= M{DKbHNCVkeHUh?=
HCC2218 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMU[2OFEh|ryP NYDsT3FvW0GQR1XS
HAL-01 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy5bXFrUUN3ME2xMlE3QTR|IN88US=> NGPBXlRUSU6JRWK=
IST-MEL1 NEXSc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\hT2lEPTB;MT6xO|Y2QSEQvF2= NELiSVBUSU6JRWK=
NCI-H719 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrETGl5UUN3ME2xMlE4QDl6IN88US=> M3PWU3NCVkeHUh?=
EVSA-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMUixNVQh|ryP M2\qZnNCVkeHUh?=
SK-NEP-1 NWPERnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXZeWNKSzVyPUGuNlAzPjZizszN NHfHR3ZUSU6JRWK=
OCUB-M M2q0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\wcoVKSzVyPUGuNlE1QDlizszN MX3TRW5ITVJ?
MEG-01 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC2TWM2OD1zLkKyNVE5KM7:TR?= MknhV2FPT0WU
no-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS5bnlKSzVyPUGuNlMyOTJizszN NFPjSGlUSU6JRWK=
MHH-CALL-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\lNWpRUUN3ME2xMlI1PzJzIN88US=> NUHKOJNRW0GQR1XS
SK-N-DZ M135PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TNZ2lEPTB;MT6yOFc4PiEQvF2= MnTQV2FPT0WU
SCLC-21H M{TjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD1zLkK2OFc5KM7:TR?= M{n0XXNCVkeHUh?=
CTV-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33rOGlEPTB;MT6yO|QzPSEQvF2= NVjrSGNOW0GQR1XS
NB1 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrZTWM2OD1zLkK3O|MzKM7:TR?= NIHMWnZUSU6JRWK=
NCI-H64 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\MZYwxUUN3ME2xMlI5PDZ{IN88US=> M3\OdHNCVkeHUh?=
MDA-MB-134-VI M1:2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHFR3lGUUN3ME2xMlI5PTd5IN88US=> MYHTRW5ITVJ?
LB2241-RCC NEDme21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwMki2OlMh|ryP MnjvV2FPT0WU
8-MG-BA NFPucZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwMki4OlYh|ryP MXrTRW5ITVJ?
LP-1 NFi4coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnmTWM2OD1zLkK5PVQ4KM7:TR?= Ml3jV2FPT0WU
LS-411N NWLoNmdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjNWYtKSzVyPUGuN|A6QThizszN M{DvV3NCVkeHUh?=
CAL-148 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;2W5JKSzVyPUGuN|I2PDJizszN Mo\RV2FPT0WU
NCI-H2171 M4W2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXrcYFKSzVyPUGuN|Q2ODJizszN MmS1V2FPT0WU
JiyoyeP-2003 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\GPVNKSzVyPUGuN|U{QSEQvF2= Mo[4V2FPT0WU
NCI-H2107 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwM{W4PFMh|ryP NV\DcohEW0GQR1XS
BB30-HNC NIPjVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrCV5VKSzVyPUGuN|g6PzhizszN M4jMcnNCVkeHUh?=
K-562 NYLUZZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD1zLkO5NlE6KM7:TR?= NVnnSWZEW0GQR1XS
PSN1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfncGJKSzVyPUGuOFIzQDdizszN MknFV2FPT0WU
HCC2157 NX75fWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnETWM2OD1zLkSyOlkyKM7:TR?= MkfuV2FPT0WU
SBC-1 M{fnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLVTWM2OD1zLkSyO|QyKM7:TR?= MojXV2FPT0WU
MC116 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwNEO2NVUh|ryP NVzIOod{W0GQR1XS
KARPAS-422 M1jQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOSohPUUN3ME2xMlQ2OzV6IN88US=> M{PhW3NCVkeHUh?=
LB996-RCC NIfLXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrTU|QyUUN3ME2xMlQ4OTB|IN88US=> MUfTRW5ITVJ?
MSTO-211H MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwNEe5PFch|ryP Ml[yV2FPT0WU
BT-474 NVPnU4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjvVHBWUUN3ME2xMlUyPzZ2IN88US=> NVHHNXNGW0GQR1XS
A388 NV;0bWdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1zLkWxPVQ2KM7:TR?= NYDvdXNPW0GQR1XS
SJSA-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fHTmlEPTB;MT61NlI3KM7:TR?= NF;lU3JUSU6JRWK=
COLO-829 MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwTmlEPTB;MT61N|U3PCEQvF2= Ml\PV2FPT0WU
KM-H2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwNU[2O{DPxE1? MUXTRW5ITVJ?
GR-ST NWXudZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXCZnVKSzVyPUGuOVY5OiEQvF2= NHTSdmtUSU6JRWK=
RPMI-8866 NX3PdGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fBZ2lEPTB;MT62NFE1PCEQvF2= MUfTRW5ITVJ?
KG-1 MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL0TmQyUUN3ME2xMlYyQTBzIN88US=> MlfUV2FPT0WU
NCI-H82 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv3WFNKSzVyPUGuOlM1ODZizszN NYDoUItyW0GQR1XS
LB1047-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PyTmlEPTB;MT62N|Q2QSEQvF2= MUnTRW5ITVJ?
KM12 NWjVU2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OySmlEPTB;MT62OFch|ryP MXrTRW5ITVJ?
NB5 NImyXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nzcmlEPTB;MT62OVY4PyEQvF2= MWrTRW5ITVJ?
HDLM-2 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwNkiyPFEh|ryP MXrTRW5ITVJ?
KU812 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNkm2NFUh|ryP M{jOd3NCVkeHUh?=
DB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\OR5BKSzVyPUGuO|A{PTNizszN MnS0V2FPT0WU
HD-MY-Z MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nVO2lEPTB;MT63OVI{PCEQvF2= MWrTRW5ITVJ?
KURAMOCHI MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwN{eyNFch|ryP NFjIfodUSU6JRWK=
ETK-1 M4PRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHwOlNKSzVyPUGuO|g5PzlizszN NYrHZ2lGW0GQR1XS
SK-UT-1 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXPS2dKSzVyPUGuO|k{QDhizszN MWnTRW5ITVJ?
HUTU-80 NGX5TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HjN2lEPTB;MT63PVUxQCEQvF2= NUi2eG9FW0GQR1XS
ES7 NEXmZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf3emZKUUN3ME2xMlgxOzB{IN88US=> NFjSTItUSU6JRWK=
SW872 M1fw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnETWM2OD1zLkixN|k2KM7:TR?= MV3TRW5ITVJ?
TK10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETobXBKSzVyPUGuPFMyODhizszN M4rpPHNCVkeHUh?=
LB831-BLC M3fkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrkTWM2OD1zLkizOVY{KM7:TR?= MmTMV2FPT0WU
TE-9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nFWGlEPTB;MT64OFQzOiEQvF2= NEXRUWFUSU6JRWK=
MLMA NGf4[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTscYNoUUN3ME2xMlg5OjN2IN88US=> NWPNbG9lW0GQR1XS
D-542MG NVq5WFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHIUHpVUUN3ME2xMlg6Ozd|IN88US=> MXHTRW5ITVJ?
EW-16 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7mRY9KSzVyPUGuPVI4OiEQvF2= MXzTRW5ITVJ?
LOXIMVI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwOUOyPEDPxE1? NYjxe4dLW0GQR1XS
GB-1 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwOUO4OlYh|ryP NFf5cY5USU6JRWK=
IST-SL2 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPXXlVDUUN3ME2yMlAxOjZ{IN88US=> NHLYeFRUSU6JRWK=
LAN-6 NX7jflRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj2elJKSzVyPUKuNFE6PjZizszN NV7yTYxFW0GQR1XS
NCI-H510A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDMcGtKSzVyPUKuNFQ2ODJizszN NYrJTZFsW0GQR1XS
NCI-H1092 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nKPWlEPTB;Mj6wOVEzPCEQvF2= M4[0VXNCVkeHUh?=
HT NEWyVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwMUC0OVQh|ryP MYDTRW5ITVJ?
RL95-2 M4S3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfjTWM2OD1{LkGxOFgzKM7:TR?= NE\B[2hUSU6JRWK=
NCI-H1355 M{K1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LaXmlEPTB;Mj6xNVc6OiEQvF2= MUPTRW5ITVJ?
NCI-H720 NXrHUmllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnrV29KSzVyPUKuNVY5PzNizszN MWPTRW5ITVJ?
NCI-H1522 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X0TmlEPTB;Mj6yNVczOyEQvF2= NWPacoUyW0GQR1XS
LB373-MEL-D NEf0fodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XJWGlEPTB;Mj6yOlkxOiEQvF2= MlO0V2FPT0WU
DG-75 NHvsd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoThTWM2OD1{LkK3NVQ5KM7:TR?= MnXDV2FPT0WU
ML-2 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJwM{K4OVUh|ryP MmTGV2FPT0WU
SF126 M4XWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwM{OwPVQh|ryP Mn7pV2FPT0WU
MPP-89 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwM{OxOFUh|ryP MlXUV2FPT0WU
NCI-H345 M3rQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzVNWpIUUN3ME2yMlM{Ojd5IN88US=> M3u2NnNCVkeHUh?=
LS-123 NYm4R5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tt[2lEPTB;Mj6zOFk{PiEQvF2= NIDyZoZUSU6JRWK=
NB10 NHvpTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDwTWM2OD1{LkSxNFkzKM7:TR?= NUK5Z4ZjW0GQR1XS
CGTH-W-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\LS4czUUN3ME2yMlQzOjZ5IN88US=> MUPTRW5ITVJ?
CP66-MEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjHelU4UUN3ME2yMlQ4PzdizszN NWXlUoNmW0GQR1XS
L-428 NUS0N29yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJwNEi1NlEh|ryP NIDrZ5hUSU6JRWK=
DMS-79 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknHTWM2OD1{LkW0NVA{KM7:TR?= M1HpXXNCVkeHUh?=
NCI-H1882 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPkRoNlUUN3ME2yMlY4PTZ{IN88US=> MlH2V2FPT0WU
KGN NWXHOZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwN{[4O|Yh|ryP NVzFc4Q1W0GQR1XS
EW-1 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO1U2h1UUN3ME2yMlc4ODh|IN88US=> MoH4V2FPT0WU
U-266 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTKTWM2OD1{Lki0PFI{KM7:TR?= NF3p[I5USU6JRWK=
COLO-320-HSR M2P6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwOEW2OFEh|ryP NXX1S4ZCW0GQR1XS
KMOE-2 NUHNOlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DXN2lEPTB;Mj64O|cyOSEQvF2= M{f3XHNCVkeHUh?=
BB49-HNC Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwOUK0PEDPxE1? NITGNZZUSU6JRWK=
GI-1 NELsfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLnTWM2OD1{LkmyPVU4KM7:TR?= MWPTRW5ITVJ?
NCI-H1304 M1;HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX5TWM2OD1|LkCwOVEyKM7:TR?= M1TL[3NCVkeHUh?=
NCI-H2227 NHPOSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwMEKwO|kh|ryP MXrTRW5ITVJ?
U-87-MG NEDVV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnrTWM2OD1|LkCzOVE{KM7:TR?= M{XFUnNCVkeHUh?=
NCI-H747 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom5TWM2OD1|LkC1NlA3KM7:TR?= MY\TRW5ITVJ?
CTB-1 NXH6RWkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETJT3RKSzVyPUOuNFU{PzZizszN Moe5V2FPT0WU
RPMI-8226 NIPL[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnue2t{UUN3ME2zMlE1Ozd6IN88US=> NEfORnRUSU6JRWK=
NCI-H2141 NHq4Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33FVGlEPTB;Mz6xOlU3PiEQvF2= M125NnNCVkeHUh?=
IST-MES1 NUC2Sm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqwTWM2OD1|LkG4Nlc6KM7:TR?= M2nnPXNCVkeHUh?=
TE-5 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3bI1KSzVyPUOuNlE{PDJizszN M2TCRXNCVkeHUh?=
UACC-257 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K3cmlEPTB;Mz60N|Y2QSEQvF2= MXTTRW5ITVJ?
SK-N-FI MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjHdFlKSzVyPUOuOFUzOjdizszN NIW1UYlUSU6JRWK=
MFH-ino NFyx[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HrfmlEPTB;Mz60OlU5QSEQvF2= NHraTm5USU6JRWK=
SF268 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHFWWIzUUN3ME2zMlQ5OTd2IN88US=> MX3TRW5ITVJ?
TE-12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv5TWM2OD1|LkWxOlk6KM7:TR?= NWjRUWdVW0GQR1XS
NB6 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTnTWM2OD1|LkW1OVY{KM7:TR?= M16y[HNCVkeHUh?=
DJM-1 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPwNJlKSzVyPUOuOVk5QTlizszN NVzpNYhJW0GQR1XS
MZ1-PC M3vGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP5UotKSzVyPUOuOlE3OjRizszN M{DycXNCVkeHUh?=
OCI-AML2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzibmxKSzVyPUOuOlI3PzFizszN NIrFZ|BUSU6JRWK=
NCI-H1155 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnwNIdKSzVyPUOuO|A6PDdizszN MXnTRW5ITVJ?
RKO NVrmUmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPLXXVpUUN3ME2zMlc4OTh7IN88US=> NI\2OmpUSU6JRWK=
ECC4 M1PnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TZZWlEPTB;Mz65O|E6PSEQvF2= MlHuV2FPT0WU
BB65-RCC NXjyeGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXITWM2OD1|Lkm3OVQ4KM7:TR?= MlSxV2FPT0WU
EB-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjUTWM2OD1|Lkm5OlM{KM7:TR?= NUezb|VqW0GQR1XS
SHP-77 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ZNnV3UUN3ME20MlAxPTJ2IN88US=> M3G0W3NCVkeHUh?=
NCI-H2196 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj1SFNTUUN3ME20MlA2PjJ3IN88US=> M3vWXXNCVkeHUh?=
GI-ME-N MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfN[ldOUUN3ME20MlA3Ozl7IN88US=> M{PLfnNCVkeHUh?=
MN-60 M4DTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7mVZZ3UUN3ME20MlExQDdizszN NV7oNYtyW0GQR1XS
NCI-H1694 M4DGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H1dGlEPTB;ND6xN|QxPSEQvF2= M3:yUXNCVkeHUh?=
LU-65 NEjYOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqUmlEPTB;ND6xOVM{OiEQvF2= Ml3YV2FPT0WU
NCI-H1436 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwMUizN|Mh|ryP M1HFbHNCVkeHUh?=
KINGS-1 M3;uPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRwM{G0N|Ih|ryP NYHwc4hHW0GQR1XS
GT3TKB NGrIXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HqO2lEPTB;ND6zN|I3QCEQvF2= M{HXO3NCVkeHUh?=
Becker MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPYTYxKSzVyPUSuN|c{OTJizszN MkL4V2FPT0WU
HCC1187 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPJVFB3UUN3ME20Mlg6PjV5IN88US=> MYrTRW5ITVJ?
D-502MG NH;aTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXtbpJQUUN3ME21MlAxPDF4IN88US=> NH2yPWlUSU6JRWK=
VA-ES-BJ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjSTWM2OD13LkGzO|c5KM7:TR?= Mni2V2FPT0WU
NB7 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132ZWlEPTB;NT6xOFEyOiEQvF2= NX7PSpRpW0GQR1XS
SW962 NXvY[nVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LoNmlEPTB;NT6zPFgyPCEQvF2= MkDiV2FPT0WU
no-11 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDKdpNKSzVyPUWuO|Y{PDNizszN NHX5co1USU6JRWK=
KNS-81-FD NIDPVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfQdGppUUN3ME21MlkxPjl2IN88US=> MVzTRW5ITVJ?
COLO-684 M4jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvJTWM2OD13Lkm5OFk1KM7:TR?= MnS5V2FPT0WU
D-263MG M4nVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe3TVdZUUN3ME22MlA5QDl3IN88US=> NWj3d|liW0GQR1XS
EW-24 M{PteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnpfWhMUUN3ME22MlI5PTFizszN Ml\QV2FPT0WU
TE-10 NV;0PFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;5XZIyUUN3ME22MlQzPjJ|IN88US=> MoXyV2FPT0WU
EKVX M1W4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TiNWlEPTB;Nj60OlMzOSEQvF2= NYHpdZZmW0GQR1XS
NCI-H1648 M2DwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4TWM2OD14Lk[3OVU4KM7:TR?= Mli3V2FPT0WU
LB771-HNC NILGUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3nTWM2OD14LkmyN|AyKM7:TR?= NFjwfpVUSU6JRWK=
SK-MEL-1 M3jMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRThwMUOxOlYh|ryP NIHkVHBUSU6JRWK=
COLO-668 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRThwMke3PFYh|ryP MWTTRW5ITVJ?
EW-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRThwNEC4NFMh|ryP NH71cYRUSU6JRWK=
A253 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRThwOES2OlEh|ryP NV20fmRWW0GQR1XS
NCI-H2126 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRThwOEmzNVkh|ryP NEXnc4lUSU6JRWK=
Calu-6 M2nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPFVHdKSzVyPUiuPVkxPDJizszN MWHTRW5ITVJ?
NCI-H23 NWrndo1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL2TWM2OD17LkG3O|Q3KM7:TR?= MkjzV2FPT0WU
WSU-NHL M3\Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfZRZI2UUN3ME25Mlc4PDd6IN88US=> M2XCU3NCVkeHUh?=
MMAC-SF NELrZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTlwOUe5NFQh|ryP NVq5fZlLW0GQR1XS
SK-LMS-1 NXjIToFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFyLkK4N|Qh|ryP MV3TRW5ITVJ?
GCIY MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP0WY5KSzVyPUGwMlU6OjRizszN MXHTRW5ITVJ?
TE-15 M1vISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fsV2lEPTB;MUGuOlAxPCEQvF2= MmrMV2FPT0WU
EoL-1-cell MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HnR2lEPTB;MUGuO|Y5OiEQvF2= MXfTRW5ITVJ?
NCI-H2081 NGjmW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnqVGVKSzVyPUGxMlc4QDZizszN NXfHbYI3W0GQR1XS
EW-3 M1\qbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7xTWM2OD1zMj6yOFY{KM7:TR?= MWrTRW5ITVJ?
CAS-1 M1yxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF{LkO2N|Eh|ryP MWTTRW5ITVJ?
C2BBe1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O0[WlEPTB;MUKuOlE{OSEQvF2= M2izWXNCVkeHUh?=
D-247MG NFuyO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\tWINPUUN3ME2xNk44QTV{IN88US=> MXXTRW5ITVJ?
NCI-SNU-5 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LmfGlEPTB;MUKuPFAyOyEQvF2= MnPqV2FPT0WU
LS-1034 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES1dWdKSzVyPUG0MlM6PzVizszN M4X4ZnNCVkeHUh?=
EW-18 NYjt[2NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Kzb2lEPTB;MUSuOFQ5KM7:TR?= MnHzV2FPT0WU
Raji MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrTdmx{UUN3ME2xOE42ODR7IN88US=> MXfTRW5ITVJ?
D-283MED MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL0OFNKSzVyPUG0MlYzPzFizszN NFv4PVVUSU6JRWK=
MZ2-MEL M3\JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF2Lkm2PVYh|ryP MWLTRW5ITVJ?
NCI-SNU-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTYWZZEUUN3ME2xOU41PjN|IN88US=> MkWyV2FPT0WU
P30-OHK MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnNZ5hKSzVyPUG3Mlc5OzFizszN MlfxV2FPT0WU
RXF393 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5RpRMUUN3ME2xPU4xOTh4IN88US=> M2XEZ3NCVkeHUh?=
NCI-H1395 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzwT3lCUUN3ME2yNE43PzB|IN88US=> NUDPbIExW0GQR1XS
U-698-M Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\4SY1jUUN3ME2yNE44ODd3IN88US=> NVTw[W16W0GQR1XS
NCI-SNU-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJyLkeyNlMh|ryP MXzTRW5ITVJ?
SW684 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnVNppKSzVyPUKxMlE4OTZizszN MX3TRW5ITVJ?
NCI-H716 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJzLkOxOVQh|ryP NEGwVGFUSU6JRWK=
JVM-2 M3;QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHVU21PUUN3ME2yNU41OTN|IN88US=> NVLUd5psW0GQR1XS
NCI-H1581 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DqN2lEPTB;MkKuOFE1QCEQvF2= M322[XNCVkeHUh?=
CA46 M{fXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfScHl4UUN3ME2zNU43QTN4IN88US=> MkDaV2FPT0WU
SNB75 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfGdJFqUUN3ME2zN{43PTB|IN88US=> NGL5OllUSU6JRWK=
KNS-42 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO5eoNKSzVyPUO1Mlk3OjRizszN MlXvV2FPT0WU
TUR Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHHcJdnUUN3ME2zOk4xPTJzIN88US=> NWewfVdXW0GQR1XS
REH M1TuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHnSnNKSzVyPUO3MlgzOTFizszN M1LHVHNCVkeHUh?=
EW-22 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPRTWM2OD12Mj6yPFg2KM7:TR?= MUDTRW5ITVJ?
NCI-H446 NYTLSI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHzfYczUUN3ME20Nk44QDV|IN88US=> M4\EN3NCVkeHUh?=
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXjNWdKSzVyPUSzMlE{OzlizszN MX7TRW5ITVJ?
EW-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jjeGlEPTB;NESuPFIyQCEQvF2= MWnTRW5ITVJ?
RH-1 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv3TWM2OD12Nz61PFEzKM7:TR?= NFrwOmRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID